Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.

Abstract

Trimetrexate glucuronate in combination therapy with cisplatin or etoposide was evaluated in non-small cell lung cancer patients in a pilot, dose escalation study. Trimetrexate was administered intravenously together with 20 mg/m2 cisplatin or 50 mg/m2 etoposide for 5 consecutive days at an initial dose of 4 mg/m2. Courses were repeated at 3 week intervals with the trimetrexate dosage escalated according to patient tolerance. In the 12 patients treated to date, reversible myelosuppression, consisting of leukopenia and thrombocytopenia, and nonhematologic grade 1 and 2 toxicities were observed. The study is ongoing. The maximum tolerated trimetrexate dosage levels in combination therapy will be established.

• Authors: J A Maroun, R B Natale, F Robert
• Journal: Seminars in oncology (Semin Oncol) Vol. 15 Issue 2 Suppl 2 Pg. 38-40 (Apr 1988) ISSN: 0093-7754 [Print] United States
• PMID: 2835818 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Quinazolines
• Etoposide
• Cisplatin
• Trimetrexate

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bone Marrow (drug effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cisplatin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Quinazolines (administration & dosage)
• Trimetrexate